Phase II: Development of a Neurovascular Magnetic Particle Imaging system with sub-millimeter resolution and real time speed for non-radiative 3D perfusion angiography
Award amount
$1,825,551Program and phase
SBIR · Phase IIAward year
2019Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- MAGNETIC INSIGHT, INC
- Proposal award date
- 2019-01-15
- Contract end date
- 2020-12-31
- UEI
- HY76TZ1Z48X4
- Solicitation number
- PA18-574
- Topic code
- NIDA
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Ultra-low distortion and noise electronics to enable a clinical MPI imaging platform
- Development of a prototype clinical theranostic platform combining Magnetic Particle Imaging (MPI) and Magnetic Fluid Hyperthermia (MFH) for the treatment of brain tumors
- Color MPI as a novel method for in vivo assessment of magnetic nanoparticle dynamics and binding
- Development of a commercial Magnetic Particle Imaging platform for the detection and quantification of localized inflammation in cancer
- Phase II: Commercialization of a preclinical Magnetic Particle Imaging system with sub-millimeter resolution, nano-molar sensitivity, and integrated CT
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Wearable Wireless Respiratory Monitoring System that Detects and Predicts Opioid Induced Respiratory Depression
- Building and testing the Life Enhancement and Advocacy Programming digital training tool (LEAPLink) to better serve people with lived experience of homelessness and substance use disorder
- A digital intervention to decrease self-stigma among pregnant and postpartum women with opioid use disorder
- Development of medication for the treatment of respiratory depression due to opioid (prescribed or illicit) overdose/multidrug (polysubstance) overdose in a hospital or community setting.
- Creation and Validation of the Dose-Opioid-Source Evaluation tool (DOSE) - a Robust Opioid Use Clinical Outcome Assessment for Qualification as an FDA Medical Device Development Tool (MDDT)
Research funding history
8 SBIR/STTR records share this UEI (2015–2023). Reported award amounts total $10,100,200. Reported amounts are not federal obligations.
Phases: Phase II, Phase I, Phase II – Direct to Phase II
Agencies: Department of Health and Human Services